Abstract:
A method and system are presented for producing an output coherent anti-stokes Raman scattering (CARS) signal of a medium. The method comprises generation of a unitary optical excitation pulse that carries a pump photon, a Stokes photon and a probe photon; and inducing a CARS process in the medium by exciting the medium by the at least one such unitary optical excitation pulse. Strong coherent non resonant background, a major problem in single-pulse CARS, is reduced by orders of magnitude by using phase-only pulse shaping or completely supressed by using phase-and-polarisation shaped pulses.
Abstract:
The present invention discloses new cyclic glycerophosphates and cyclic popanediol phosphates, pharmaceutical compositions comprising said compounds and the use thereof in stimulating of target cells, in particular, enhancing the expression of various proteins within the cell. Such enhancement is used in differentiation therapy.
Abstract:
The present invention is based on the finding that Gal-8 binds to carbohydrates of cell surface CD44std and CD44v and activates a chain of biological events within the cells. A specific effect exhibited was the induction of apoptosis in the CD44std and CD44v expressing cells. Thus, the present invention concerns the use of an active agent for achieving a therapeutic effect on a target cell, the therapeutic effect comprises binding of said active agent to a standard CD44 (CD44std) glycoprotein or to a CD44 variant (CD44v) expressed by said target cell, the active agent being galectin-8 (Gal-8) or a functional derivative thereof. The active ingredient may be used for the preparation of a pharmaceutical composition, for the treatment of a disease or a disorder or for diagnostic purposes.
Abstract:
A transparent radiation delivery waveguide (3) and a guided radiation receiver assembly (1, 7) using the same, which assembly comprises a first transparent medium (6) with a first refraction index n1, a receiver chamber (1) having an aperture (2) and holding a second transparent medium (7) having a second refraction index n2, and the transparent radiation delivery waveguide (3) having a third refraction index n3 substantially equal to or greater than n1. The radiation delivery waveguide (3) consists of a transparent vessel (9) holding a transparent liquid medium (10) and has a first radiation intake portion in optical contact with the first transparent medium (6) and held tightly within the aperture (2) of the receiver chamber (1), and a second, tapered radiation delivery portion of non-circular cross-sectional shape, projecting into the receiver chamber (1).
Abstract:
Extraction of guided radiation from a waveguide (3) into a receiver chamber (1). The radiation arrives via a transparent medium and is extracted into the receiver chamber (1) holding a medium having smaller refraction index than the transparent medium, via a delivery waveguide (3) whose refraction index is equal to or greater than that of the transparent medium. The delivery waveguide (3) has a tapering radiation (5) delivery portion of non-circular cross sectional shape which projects into the receiver chamber (1).
Abstract:
Peptides having at least seven amino acids, preferably up to 20 amino acids, and most preferably 7 to 9 amino acids, comprising an amino acid sequence which corresponds to positions 180-186 of the Mycobacterium tuberculosis protein hsp 65 having the formula TFGLQLE, but differing therefrom by one to three amino acid substitutions in the positions 181-183, are disclosed. These peptides inhibit antigen recognition by T lymphocytes, such as recognition of hsp 65, and are capable of protecting a subject from an immune-related disease, such as autoimmune arthritis and to prevent rejection of a transplanted organ or tissue. Single amino acid substitutions, in particular with alanine, at positions corresponding to hsp 65 positions 183 and 181 are preferred. T cell lines specific for the above peptides and their use in treating or preventing immune-related disease is also disclosed.
Abstract:
Disclosed herein are antiviral agents, pharmaceutical formulations comprising effective amounts of these agents and methods for treating mammals suffering from infections caused by viruses. The agents are analogs, isomers, homologs, derivatives and salts of aromatic polycyclic diones.
Abstract:
The invention provides a multilayered nanostructure comprising at least one first layered nanotube being of at least one first inorganic material and having an inner void holding at least one second layered nanotube being of at least one second inorganic material; wherein said at least one first nanotube and at least one second nanotube differ in at least one of structure and material. The invention further provides processes for the manufacture of multilayered nanostructures and uses thereof.
Abstract:
The present invention relates to a novel system and method for the determination of depth profiling with improved accuracy and reliability. The method comprises obtaining spectroscopic data from the sample while under at least two different electrical conditions of the sample, the spectroscopic data comprising a signal of charged particles emitted from the sample, and being indicative of a change in amplitude, spectral position and spectral shape of the signal from the sample while under different electrical conditions of the sample, the change being indicative of the compositional profile and spatial distribution for at least one chemical element in the sample along a direction through the sample.
Abstract:
The present invention relates to a drug delivery device that is useful for topical treatment of various infections such as skin and nail, or vaginal infections. More specifically, the invention provides a device for topical administration of allicin to an infection site, comprising either one solid carrier or two adjacent solid carriers, dry alliin and dry alliinase, wherein either a mixture of said dry alliin and dry alliinase is contained within said one solid carrier or dry alliin and dry alliinase are each separately contained within each one of said two adjacent solid carriers, whereby in contact with the infection site and a wetting agent, the alliinase acts on the alliin and allicin is produced in situ and administered to the infection site